Stage II/III CRC: negative prognostic role for BRAF mutation

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In this meta-analysis, BRAF mutation was significantly associated with shorter disease-free survival (DFS) and overall survival (OS) among patients with stage II/III colorectal cancer (CRC) receiving adjuvant chemotherapy after curative resection.

Key results

  • Total of 7 phase III randomized clinical trials involving 1,035 patients with BRAF mutation and stage II/III CRC receiving curative resection and adjuvant chemotherapy were analyzed.
  • BRAF mutation resulted in poorer OS (HR=1.42; 95% CI, 1.25-1.60; P<.00001), and poorer DFS (HR=1.26; 95% CI, 1.07-1.48, P=.006) vs BRAF wild-type CRC.
  • Prognostic role in recurrence-free survival could not be elucidated because of limited da...